Literature DB >> 18385603

Rifaximin in treatment of recurrent Clostridium difficile-associated diarrhea: an uncontrolled pilot study.

Kevin W Garey, Zhi-Dong Jiang, Angelle Bellard, Herbert L Dupont.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 18385603     DOI: 10.1097/MCG.0b013e31814a4e97

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


× No keyword cloud information.
  29 in total

Review 1.  Clostridium difficile infection: update on emerging antibiotic treatment options and antibiotic resistance.

Authors:  Dhara Shah; Minh-Duc Dang; Rodrigo Hasbun; Hoonmo L Koo; Zhi-Dong Jiang; Herbert L DuPont; Kevin W Garey
Journal:  Expert Rev Anti Infect Ther       Date:  2010-05       Impact factor: 5.091

Review 2.  Future novel therapeutic agents for Clostridium difficile infection.

Authors:  Hoonmo L Koo; Kevin W Garey; Herbert L Dupont
Journal:  Expert Opin Investig Drugs       Date:  2010-07       Impact factor: 6.206

Review 3.  Treatment of refractory and recurrent Clostridium difficile infection.

Authors:  Christina M Surawicz; Jacob Alexander
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-04-19       Impact factor: 46.802

Review 4.  Recurrent Clostridium difficile infection: what are the treatment options?

Authors:  Claire M F van Nispen tot Pannerden; Annelies Verbon; Ernst J Kuipers
Journal:  Drugs       Date:  2011-05-07       Impact factor: 9.546

5.  Management of Clostridium difficile Infection.

Authors:  Layth S Al-Jashaami; Herbert L DuPont
Journal:  Gastroenterol Hepatol (N Y)       Date:  2016-10

6.  Clostridium difficile infection: risk factors, diagnosis and management.

Authors:  Christina M Surawicz
Journal:  Curr Treat Options Gastroenterol       Date:  2015-03

7.  Preoperative Clostridium difficile infection is not associated with an increased risk for the infection in ileal pouch patients.

Authors:  Chao Sun; Peng Du; Xian-rui Wu; Elaine Queener; Bo Shen
Journal:  Dig Dis Sci       Date:  2014-02-07       Impact factor: 3.199

8.  Therapeutic Success of Rifaximin for Clostridium difficile Infection Refractory to Metronidazole and Vancomycin.

Authors:  George Tannous; Guy Neff; Nyingi Kemmer
Journal:  Case Rep Gastroenterol       Date:  2010-09-28

Review 9.  Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases.

Authors:  Hoonmo L Koo; Herbert L DuPont
Journal:  Curr Opin Gastroenterol       Date:  2010-01       Impact factor: 3.287

10.  The role of rifaximin in the treatment and chemoprophylaxis of travelers' diarrhea.

Authors:  Hoonmo L Koo; Herbert L Dupont; David B Huang
Journal:  Ther Clin Risk Manag       Date:  2009-11-02       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.